magicJack VocalTec
NASDAQ:CALLmagicJack VocalTec Ltd., together with its subsidiaries, operates as a cloud communications company in the United States. The company's products and services allow users to make and/or receive free telephone calls to and from where the customer has broadband access to the Internet. It provides magicJack devices, such as The magicJack, magicJack PLUS, New magicJack PLUS, magicJack GO, and magicJack EXPRESS, which are voice-over-Internet-Protocol (VoIP) devices that enables customers to receive free VoIP phone service for their home, enterprise, or while traveling. The company also offers magicJack APP, an application that allows users to make and receive telephone calls through their smart phones using their magicJack account, as well as access to servers for a fee on a monthly or annual basis; and magicJack Connect App that offers Wi-Fi app-to-app calling and messaging services, as well as unlimited calling plans for the United States subscribers. In addition, it provides other magicJack-related products; and wholesales telephone services to VoIP providers and telecommunication carriers. Further, the company offers hosted unified communication as a service, as well as sells related hardware and network equipment to blue chip corporate customers; and VoIP services to small to medium sized businesses. It distributes its products through retail outlets, as well as direct sales. magicJack VocalTec Ltd. was founded in 1989 and is headquartered in Netanya, Israel.
Terns Pharmaceuticals
NASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Veris Residential
NYSE:VREVeris Residential, Inc. is a forward-thinking, environmentally and socially conscious real estate investment trust (REIT) that primarily owns, operates, acquires and develops holistically-inspired, Class A multifamily properties that meet the sustainability-conscious lifestyle needs of today's residents while seeking to positively impact the communities it serves and the planet at large. The company is guided by an experienced management team and Board of Directors and is underpinned by leading corporate governance principle; a best-in-class and sustainable approach to operations; and an inclusive culture based on equality and meritocratic empowerment.